logo

WST

West Pharmaceutical·NYSE
--
--(--)
--
--(--)
9.63 / 10
Outperform

WST's fundamental analysis is rated Outperform with a 9.6/10 score. Key strengths include a high net income-to-revenue ratio (0.3478), robust cash-to-market-value (-0.6757), and an impressive ROA of 9.3326%, all of which rank in top performance groups. However, revenue-to-market-value (-0.7703) and asset-to-market-value (-0.5007) are negative, placing them in lower quartiles and indicating potential valuation concerns. These mixed signals across factors result in an overall outstanding yet not flawless fundamental picture.

Fundamental(9.63)SentimentTechnical

Analysis Checks(8/10)

Revenue-MV
Value-0.77
Score0/3
Weight-62.10%
1M Return-3.84%
ROA (%)
Value9.33
Score3/3
Weight20.24%
1M Return1.03%
Net profit attributable to parent company shareholders / Net profit (%)
Value100.00
Score2/3
Weight-28.46%
1M Return-1.71%
Net income-Revenue
Value0.35
Score2/3
Weight57.11%
1M Return2.59%
Cash-UP
Value-0.08
Score3/3
Weight83.32%
1M Return3.93%
Annualized net profit margin on total assets (%)
Value12.44
Score3/3
Weight20.24%
1M Return1.03%
Interest coverage ratio (EBIT / Interest expense) (%)
Value15.48
Score2/3
Weight-32.08%
1M Return-1.95%
Asset-MV
Value-0.50
Score0/3
Weight-53.75%
1M Return-3.57%
Cash-MV
Value-0.68
Score2/3
Weight71.67%
1M Return3.31%
Net profit / Total profit (%)
Value80.37
Score3/3
Weight23.82%
1M Return1.20%
Is WST undervalued or overvalued?
  • WST scores 9.63/10 on fundamentals and holds a Discounted valuation at present. Backed by its 12.61% ROE, 16.29% net margin, 36.43 P/E ratio, 5.87 P/B ratio, and -0.29% earnings growth, these metrics solidify its Outperform investment rating.